Percivia Revenue and Competitors
Estimated Revenue & Valuation
- Percivia's estimated annual revenue is currently $1.4M per year.
- Percivia's estimated revenue per employee is $155,000
Employee Data
- Percivia has 9 Employees.
- Percivia grew their employee count by -18% last year.
Percivia's People
| Name | Title | Email/Phone |
|---|
Percivia Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Percivia?
PERCIVIA is a venture formed by Crucell N.V. and Royal DSM N.V., to develop recombinant therapeutic proteins using the PER.C6® human cell line, with a focus on biosimilar monoclonal antibodies globally. Additionally, PERCIVIA out-licenses the PER.C6® cell line and provides logistical support by training and advising on the methods of recombinant protein production using the technology to licensees. PERCIVIA’s unique advantage lies in the core technologies of PER.C6®, the company’s high yield proprietary human cell line, which enables SCALEâ„¢, a market-optimized manufacturing process, allowing for rapid facility set up with an “In Market, For Marketâ€â„¢ manufacturing solution.
keywords:N/A
N/A
Total Funding
9
Number of Employees
$1.4M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | -10% | N/A |
#4 | $0.7M | 9 | -71% | $138.8M |
#5 | $0.7M | 9 | -25% | N/A |